Study results pending publication in July print edition of Clinical Chemistry, available on Web INDIANAPOLIS, July 23, 2008 /PRNewswire/ -- A Roche Diagnostics-sponsored pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide (NT-proBNP) confirms the potential value of NT-proBNP for risk stratification in predicting the risk of cardiovascular adverse events (CV-AE) in patients treated with non-steroidal anti-inflammatory drugs of the COX inhibitor class. The complete results of the study, currently available at www.clinchem.org , are scheduled for publication in the July print edition of Clinical Chemistry. Non-steroidal anti-inflammatory drugs (NSAIDs) -- for example, acetylsalicylic acid and ibuprofen -- are the best known inhibitors of COX (cyclo-oxygenase), an enzyme involved in the inflammation...
[read full story]
Your Web Site
